Study finds beta blockers offer no benefit after uncomplicated heart attacks

A major international trial has found that beta blockers provide no benefit for patients who suffer uncomplicated heart attacks but retain normal heart function. The REBOOT trial results challenge decades of standard medical practice. Women in the study faced higher risks when taking the drugs.

The REBOOT trial enrolled 8505 patients across 109 hospitals in Spain and Italy. Participants were randomly assigned to receive beta blockers or avoid them after hospital discharge, while all received modern standard care. Researchers followed them for a median of nearly four years and found no significant reduction in death, repeat heart attacks, or heart failure hospitalizations among those with preserved heart function.

Liittyvät artikkelit

Illustration of a doctor discussing positive kidney treatment results with a patient using digital graphs.
AI:n luoma kuva

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

Raportoinut AI AI:n luoma kuva Faktatarkistettu

New data presented at the European Renal Association’s 63rd Congress in Glasgow and published in three major medical journals found that finerenone slowed kidney-function decline in adults with chronic kidney disease (CKD) without diabetes and reduced the risk of a combined kidney-and-cardiovascular outcome. A separate pooled analysis that combined results across finerenone studies also reported fewer kidney and heart-failure events in a broader CKD population.

Two existing medications cooled core body temperature in animals after stroke and reduced brain damage. A small human trial showed limited effect due to slow delivery. Researchers are now planning a follow-up study with faster infusions.

Raportoinut AI

A major Cochrane review of 17 clinical trials involving over 20,000 participants has concluded that drugs targeting amyloid beta in the brain provide no meaningful benefits for patients with mild cognitive impairment or early Alzheimer’s. These treatments also raise the risk of brain swelling and bleeding. Researchers urge a shift to alternative pathways for future treatments.

Tämä verkkosivusto käyttää evästeitä

Käytämme evästeitä analyysiä varten parantaaksemme sivustoamme. Lue tietosuojakäytäntömme tietosuojakäytäntö lisätietoja varten.
Hylkää